WO2006063717A3 - Polymerase-independent analysis of the sequence of polynucleotides - Google Patents

Polymerase-independent analysis of the sequence of polynucleotides Download PDF

Info

Publication number
WO2006063717A3
WO2006063717A3 PCT/EP2005/013062 EP2005013062W WO2006063717A3 WO 2006063717 A3 WO2006063717 A3 WO 2006063717A3 EP 2005013062 W EP2005013062 W EP 2005013062W WO 2006063717 A3 WO2006063717 A3 WO 2006063717A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
polymerase
sequence
methods
independent analysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/013062
Other languages
French (fr)
Other versions
WO2006063717A2 (en
Inventor
Stuetz Jan Andre Rojas
Eric Kervio
Clemens Richert
Patrizia Hagenbuch
Annette Hochgesand
Niels Griesang
Stephanie Vogel
Ulrich Plutowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karlsruher Institut fuer Technologie KIT
Original Assignee
Universitaet Karlsruhe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Karlsruhe filed Critical Universitaet Karlsruhe
Priority to EP05811690A priority Critical patent/EP1828217A2/en
Priority to US11/721,914 priority patent/US20100029008A1/en
Publication of WO2006063717A2 publication Critical patent/WO2006063717A2/en
Publication of WO2006063717A3 publication Critical patent/WO2006063717A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention concerns methods of polymerase independent template directed elongation of polynucleotides, nucleotide building blocks used in these methods as well as the use of the methods and building blocks for the determination of nucleotide sequences, in particular for the determination of SNPs, base modifications, mutations, rearrangements and methylation patterns.
PCT/EP2005/013062 2004-12-16 2005-12-06 Polymerase-independent analysis of the sequence of polynucleotides Ceased WO2006063717A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05811690A EP1828217A2 (en) 2004-12-16 2005-12-06 Polymerase-independent analysis of the sequence of polynucleotides
US11/721,914 US20100029008A1 (en) 2004-12-16 2005-12-12 Polymerase-independent analysis of the sequence of polynucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04029858 2004-12-16
EP04029858.0 2004-12-16

Publications (2)

Publication Number Publication Date
WO2006063717A2 WO2006063717A2 (en) 2006-06-22
WO2006063717A3 true WO2006063717A3 (en) 2006-11-30

Family

ID=35789003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/013062 Ceased WO2006063717A2 (en) 2004-12-16 2005-12-06 Polymerase-independent analysis of the sequence of polynucleotides

Country Status (3)

Country Link
US (1) US20100029008A1 (en)
EP (1) EP1828217A2 (en)
WO (1) WO2006063717A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7582618B2 (en) 2002-06-28 2009-09-01 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
US7608597B2 (en) 2000-05-23 2009-10-27 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080021797A (en) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 Methods and compositions for treatment of flaviviruses and pestiviruses
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
US7746865B2 (en) 2004-12-07 2010-06-29 Intel Corporation Maskable content addressable memory
US8975026B2 (en) * 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
FR2913424B1 (en) * 2007-03-09 2009-07-24 Cis Bio Internat Sa CYANINE DERIVATIVES, FLUORESCENT CONJUGATES CONTAINING SAME AND USE THEREOF
US8524898B2 (en) * 2007-05-16 2013-09-03 Luxembourg Bio Technologies Ltd. Proton acceptor iminium/carbocation-type coupling agents
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL3290428T3 (en) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
PT2609923T (en) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
EP3345915B1 (en) 2010-04-12 2021-11-24 Somalogic, Inc. 5-position modified pyrimidines and their use
UA117095C2 (en) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. NUCLEOSIDE COMPOUND OR PHARMACEUTICALALLY SUITABLE SALT
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EA201690473A1 (en) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи COMBINED COMPOSITION OF TWO ANTI-VIRUS COMPOUNDS
EP3055319A4 (en) 2013-10-11 2018-01-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112016010165A2 (en) 2013-11-21 2017-12-05 Somalogic Inc cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2017221929A1 (en) * 2016-06-21 2017-12-28 株式会社ジーンデザイン Method for synthesizing ribonucleic acid h-phosphonate monomer, and oligonucleotide synthesis in which said monomer is used
DK3512863T3 (en) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2β-substituted-N6-substituted purine nucleotides for the treatment of RNA virus
CN115477679A (en) 2017-02-01 2022-12-16 阿堤亚制药公司 Nucleotide hemisulfates for the treatment of hepatitis C virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
WO2020010495A1 (en) * 2018-07-09 2020-01-16 深圳华大智造极创科技有限公司 Method for nucleic acid sequencing
TWI775313B (en) 2020-02-18 2022-08-21 美商基利科學股份有限公司 Antiviral compounds
TWI794742B (en) 2020-02-18 2023-03-01 美商基利科學股份有限公司 Antiviral compounds
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR20240022574A (en) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. Favorable anti-HCV combination therapy
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914193A (en) * 1984-06-08 1990-04-03 Toagosei Chemical Industry Co., Ltd. 5'-O-Triorganostannyl derivatives of deoxynucleosides or deoxynucleotides and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) * 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US7033753B1 (en) * 1999-01-15 2006-04-25 University Of Rochester Compositions and methods for nonenzymatic ligation of oligonucleotides and detection of genetic polymorphisms
US6958215B1 (en) * 1999-03-15 2005-10-25 Geron Corporation Methods and compositions for inhibition of RNA splicing
CN1317291C (en) * 1999-09-10 2007-05-23 杰龙公司 Oligonucleotide N3'-P5' thiophosphoramidates, their synthesis and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914193A (en) * 1984-06-08 1990-04-03 Toagosei Chemical Industry Co., Ltd. 5'-O-Triorganostannyl derivatives of deoxynucleosides or deoxynucleotides and their uses

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. OHKUBU ET AL.: "O-Selectivity and utility of phosphorylation mediated by phosphite triester intermediated in the N-unprotected phosphoramidite method", J. AM. CHEM. SOC., vol. 126, 2004, pages 10884 - 10896, XP002370142 *
ALBERICIO F ET AL: "COUPLING REAGENT AND ACTIVATION", METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 289, 1997, pages 104 - 126, XP001021224, ISSN: 0076-6879 *
C. SCHATTENKERK ET AL.: "Synthesis of a naturally occurring nucleopeptide fragment via a phosphotriester approach", TETRAHEDRON LETTERS, vol. 25, 1984, pages 5197 - 5200, XP002370141 *
C.B. REESE ET AL.: "Acid-catalysed hydrolysis of adenosine 5'-phosphorodithiomorpholidate", TETRAHEDRON LETTERS, vol. 35, 1994, pages 5085 - 5088, XP002370140 *
J.A. ROJAS STÜTZ, C. RICHERT: "A steroid cap adjusts the selectivity and accelerates the rates of nonenzymatic single nucleotide extensions of an oligonucleotide", J. AM. CHEM. SOC., vol. 123, 2001, pages 12718 - 12719, XP002370138 *
L.E. ORGEL: "Prebiotic chemistry and the origin of the RNA world", CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 39, 2004, pages 99 - 123, XP002370139 *
M. KURZ ET AL.: "Acridine-labeled primers as tools for the study of nonenzymatic RNA oligomerization", HELV. CHIM. ACTA, vol. 81, 1998, pages 1156 - 1180, XP002370144 *
S. CHANDRASEGARAN ET AL: "31P NMR Study of the mechanism of activation and coupling reactions in the synthesis of oligodeoxyribonucleotides by the phosphotriester method", J. ORG. CHEM., vol. 49, 1984, pages 4951 - 4957, XP002370143 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608597B2 (en) 2000-05-23 2009-10-27 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US8299038B2 (en) 2000-05-23 2012-10-30 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7582618B2 (en) 2002-06-28 2009-09-01 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
WO2006063717A2 (en) 2006-06-22
US20100029008A1 (en) 2010-02-04
EP1828217A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
WO2006063717A3 (en) Polymerase-independent analysis of the sequence of polynucleotides
EP4249602A3 (en) Method of preparing libraries of template polynucleotides
WO2006074351A3 (en) Reversible nucleotide terminators and uses thereof
SI3363809T1 (en) Modified nucleotides for polynucleotide sequencing
EG25197A (en) Process for the manufacture of 1,2-dichloroethane
EG25196A (en) Process for the manufacture of 1,2-Dichloroethane
WO2006113466A8 (en) Methods and nucleic acids for analyses of cellular proliferative disorders
AP3062A (en) Genotypes, alleles and molecular markers associated with asian soybean rust, as wel as methods, processes and uses thereof
DE602004014462D1 (en) Aqueous dispersions containing fluorinated polymers
WO2007041342A3 (en) Labeled nucleotide analogs and uses therefor
WO2004092418A3 (en) Global amplification using a randomly primed composite primer
DE60326697D1 (en) HAIR-RESISTANT COMPOSITIONS, POLYMERS AND METHODS
TWI365179B (en) Process for the manufacture of 1,2-dichloroethane
WO2006097320A3 (en) Macromolecular nucleotide links and methods for their use
DK1910562T3 (en) Strategies for high throughput identification and detection of polymorphisms
AU2003294474A8 (en) Compositions, methods and kits for polynucleotide amplification reactions and microfluidic devices
AU2003254597A8 (en) Dna chip based genetic typing
DK1616178T3 (en) Comparative genomic hybridization
WO2004031402A3 (en) Methylation profile of cancer
WO2004029283A3 (en) Subtelomeric dna probes and method of producing the same
WO2005052133A3 (en) Method and markers for determining the genotype of horned/polled cattle
EP1685149A4 (en) Primers, methods and kits for detecting killer-cell immunoglobulin-like receptor alleles
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer
WO2007095007A3 (en) Systematic genomic library and uses thereof
EP1819834B8 (en) Tools and methods for the quantification of dna repeats

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11721914

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005811690

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005811690

Country of ref document: EP